Orphazyme ApS Snags $19.7M In Series A for Hsp70 Program

Danish biopharmaceutical company Orphazyme ApS raised €14 million (US$19.7 million) in a Series A financing to move its lead program, Orph-001, into the clinic. The company, based in Copenhagen, is pursuing technology related to molecular chaperone heat-shock protein 70 (Hsp70) to treat disorders known as lysosomal storage diseases (LSD) – a family of more than 45 often-fatal genetic disorders with few existing treatment options.